Flu & COVID Co-infection: Higher Risk of Severe Illness | Medscape

European regulators have endorsed the first vaccine designed to protect against both COVID-19 and influenza, a development that could simplify vaccination schedules and potentially offer broader protection against respiratory illnesses. The European Medicines Agency (EMA) backing, announced this week, comes as public health officials continue to monitor the evolving landscape of respiratory viruses.

Co-infection Risks and the Rationale for Combination Vaccines

The decision to approve a combined vaccine is rooted in growing evidence that simultaneous infection with influenza and SARS-CoV-2, the virus that causes COVID-19, can lead to more severe illness than infection with either virus alone. This phenomenon, known as co-infection, places a greater burden on healthcare systems and increases the risk of complications for individuals. The EMA’s approval signals a shift towards proactive strategies to address the ongoing threat of respiratory viruses, particularly as new variants emerge.

Understanding the interplay between these viruses is crucial. Both influenza and SARS-CoV-2 are respiratory pathogens that spread through similar routes – primarily through droplets and aerosols produced when an infected person coughs, sneezes, or talks. This overlap in transmission pathways increases the likelihood of co-infection, especially during peak respiratory virus seasons.

How the Combined mRNA Vaccine Works

The newly approved vaccine utilizes messenger RNA (mRNA) technology, a platform that has proven effective in the development of COVID-19 vaccines. MRNA vaccines work by delivering genetic instructions to the body’s cells, prompting them to produce a harmless piece of the virus – typically a protein – that triggers an immune response. This allows the body to develop antibodies and immune cells that can recognize and fight off the virus if exposed in the future. The combined vaccine delivers mRNA sequences for both influenza and SARS-CoV-2, providing protection against both viruses with a single dose.

Even as the specific details of the vaccine’s composition and efficacy are still emerging, the EMA’s assessment suggests a favorable safety profile and a robust immune response. Further data on the vaccine’s performance in real-world settings will be closely monitored as it becomes available.

European Surveillance and the Respiratory Virus Landscape

The EMA’s decision arrives within a broader context of ongoing respiratory virus surveillance across Europe. The European Respiratory Virus Surveillance Summary (ERVISS), maintained by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe, provides a weekly overview of influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 activity across the European Union/European Economic Area (EU/EEA) and the WHO European Region. This integrated surveillance system is essential for tracking trends, identifying outbreaks, and informing public health interventions.

ERVISS data helps to characterize the circulating strains of each virus, assess the severity of illness, and monitor the effectiveness of vaccines. The information gathered through this surveillance network is critical for guiding vaccination strategies and ensuring that public health resources are allocated effectively. The dashboard, available at erviss.org, offers a detailed look at the epidemiological and virological situation across the region.

Understanding Integrated Surveillance

Integrated respiratory virus surveillance, as outlined in ECDC operational considerations, moves beyond tracking viruses in isolation. It recognizes that multiple respiratory pathogens can circulate simultaneously, and that interactions between them can influence disease patterns. This approach allows for a more comprehensive understanding of the overall burden of respiratory illness and facilitates more targeted public health responses.

What Which means for Public Health and Vaccination Strategies

The approval of a combined COVID-19 and influenza vaccine represents a significant step forward in the fight against respiratory illnesses. Simplifying the vaccination process – offering protection against two major threats with a single shot – could improve vaccine uptake and reduce the burden on healthcare systems. However, it’s important to note that this vaccine is not a substitute for other preventive measures, such as practicing good hygiene, staying home when sick, and following public health recommendations.

The introduction of a combined vaccine too raises logistical considerations. Healthcare providers will need to adapt their vaccination schedules and ensure that individuals are aware of the new option. Ongoing monitoring of vaccine effectiveness and safety will be crucial to assess its long-term impact.

Next Steps: Ongoing Evaluation and Potential Expansion

Following the EMA’s approval, the vaccine will undergo further review by national regulatory authorities across Europe. Each country will determine how to incorporate the combined vaccine into its national immunization programs. The EMA will continue to monitor the vaccine’s safety and effectiveness through ongoing pharmacovigilance activities.

Looking ahead, researchers are exploring the possibility of developing even more comprehensive respiratory virus vaccines that could protect against a wider range of pathogens. The success of the mRNA technology platform has opened up new avenues for vaccine development, and ongoing research is focused on improving vaccine efficacy, durability, and breadth of protection. The potential for a universal respiratory virus vaccine remains a long-term goal, but the approval of the first combined vaccine represents a significant milestone on that path.